

Day : Tuesday
 Date: 7/2/2002
 Time: 09:23:42

PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = HALPERN

First Name = MICHAEL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09101226	Not Issued	161	07/02/1998	CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES	HALPERN , MICHAEL S.
09167322	6365151	150	10/07/1998	CELLULAR IMMUNOGENS COMPRISING COGNATE PROTO-OXOGENES	HALPERN , MICHAEL S.
09366007	Not Issued	093	08/02/1999	COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ESTIMATING COSTS AND BENEFITS ASSOCIATED WITH DISEASE MANAGEMENT INTERVENTIONS	HALPERN , MICHAEL T.
09744406	Not Issued	071	01/22/2001	ALLOGENEIC CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES	HALPERN, MICHAEL S.
09966160	Not Issued	030	09/28/2001	TRANSACTION SYSTEM AND METHOD FOR VALUE CARDS	HALPERN, MICHAEL E.
09966162	Not Issued	030	09/28/2001	SYSTEM AND METHOD OF CONFIGURING VALUE CARDS	HALPERN, MICHAEL E.
10048607	Not Issued	020	01/02/2002	COMPUTER-IMPLEMENTED METHODS AND SYSTEMS FOR ESTIMATING COSTS AND BENEFITS ASSOCIATED WITH DISEASE MANAGEMENT INTERVENTIONS	HALPERN, MICHAEL T.
10093148	Not Issued	020	03/07/2002	SYSTEM AND METHOD OF SCHEDULING ASSISTED-SERVICE TRAVEL TERMINAL REPRESENTATIVES	HALPERN, MICHAEL EDWARD
10093157	Not Issued	020	03/07/2002	SYSTEM AND METHOD OF DEPLOYING SELF-SERVICE TRAVEL TERMINALS	HALPERN, MICHAEL E.
10093176	Not Issued	020	03/07/2002	SYSTEM AND METHOD OF PROCESSING PASSENGER REQUESTS	HALPERN, MICHAEL E.

REQUESTS					
<u>10101584</u>	Not Issued	020	03/20/2002	METHOD OF CONTROLLING A SELF-SERVICE TERMINAL	HALPERN, MICHAEL E.
<u>60010262</u>	Not Issued	159	01/19/1996	VACCINE STRATEGY AGAINST HUMAN TUMORS EXHIBITING PROTOONCOGENE OVEREXPRESSION	HALPERN, MICHAEL S.
<u>60093965</u>	Not Issued	159	07/24/1998	ALLOGENEIC CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES	HALPERN, MICHAEL S.

Inventor Search Completed: No Records to Display.

	Last Name	First Name
Search Another:	<input type="text" value="HALPERN"/>	<input type="text" value="MICHAEL"/>
Inventor	<input type="button" value="Search"/>	

(To go back use Back button on your browser toolbar.)

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

Day : Tuesday
 Date: 7/2/2002
 Time: 09:23:17

PALM INTRANET

Inventor Name Search Result

Your Search was:

Last Name = ENGLAND

First Name = JAMES M.

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09111885	6249234	150	07/08/1998	POSITION DETECTOR	ENGLAND , JAMES M.C.
09167322	6365151	150	10/07/1998	CELLULAR IMMUNOGENS COMPRISING COGNATE PROTO-OXOGENES	ENGLAND , JAMES M.
09744406	Not Issued	071	01/22/2001	ALLOGENIC CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES	ENGLAND, JAMES M.
60010262	Not Issued	159	01/19/1996	VACCINE STRATEGY AGAINST HUMAN TUMORS EXHIBITING PROTOONCOGENE OVEREXPRESSION	ENGLAND , JAMES M.
60093965	Not Issued	159	07/24/1998	ALLOGENIC CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES	ENGLAND , JAMES M.

Inventor Search Completed: No Records to Display.

Search Another:
Inventor

Last Name

First Name

(To go back use Back button on your browser toolbar.)

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

DT Journal: Article: (JOURNAL ARTICLE)
 FS MEDL: L; Priority: Journals; Cancer Journals
 LA English
 OS MEDLINE 92097142
 EM 199203
 L2 ANSWER 3 OF 16 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998-3119684 BIOSIS
 DN PREV19980319684
 TI Specific cell-mediated cytotoxicity against an allogeneic target cell line
 in isogenic gilbuna crucian carp.
 AU Hasegawa, Satoshi; Nakayasu, Chiaya; Yoshitomi, Tomoyasu; Nakaniishi,
 Teruyuki; Okamoto, Nobuaki (11)
 CS (11) dep. Aquatic Biosci., Tokyo Univ. Fisheries, Konan 4, Minato-ku, Tokyo
 108 Japan
 SO Fish & Shellfish Immunology, (May, 1998) Vol. 8, No. 4, pp. 303-313.
 ISSN: 1050-4648.
 DT Article
 LA English
 L2 ANSWER 4 OF 16 USPATFULL
 AN 2002-133468 USPATFULL
 TI 32 Human secreted proteins
 IN Ni, Jian, Germantown, MD, UNITED STATES
 Baker, Kevin P., Darnestown, MD, UNITED STATES
 Birse, Charles E., North Potomac, MD, UNITED STATES
 Biner, Reinhard, Gaithersburg, MD, UNITED STATES
 Fischella, Michelle, Bethesda, MD, UNITED STATES
 Komatsoulis, George A., Silver Spring, MD, UNITED STATES
 LaFleur, David W., Washington, DC, UNITED STATES
 Moore, Paul A., Germantown, MD, UNITED STATES
 Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Soper, Daniel R., Centreville, VA, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Wei, Ring, Brookville, MD, UNITED STATES
 Florence, Kimberly A., Rockville, MD, UNITED STATES
 PI US 200206311 Al 20020606
 AI US 2001-800729 Al 20010308 (9)
 RLI Continuation-in-part of Ser. No. WO 2000-US26013, filed on 22 Sep 2000,
 UNKNOWN US 1999-155709P 19990924 (60)
 PRAI Utility
 DT
 FS APPLICATION
 LN CNT 36556
 INCL INCLM: 435/069, 100
 INCLS: 435/007, 100; 435/325, 000; 435/183, 000; 536/023, 500; 530/388, 100
 NCL NCLM: 435/069, 100
 NCLS: 435/007, 100; 435/325, 000; 435/183, 000; 536/023, 500; 530/388, 100
 IC [7] ICM: A61K039-95
 ICM: C12P021-02
 ICS: C12N005-06; G01N033-53; C07H021-04; C12N009-00
 L2 ANSWER 5 OF 16 USPATFULL
 AN 2001-133945 USPATFULL
 TI Cancer immunotherapy using autologous tumor cells combined with cells
 expressing a membrane cytokine
 IN Hiscock, John C., Huntington Beach, CA, United States
 Gratz, Martin R., Richmond, VA, United States
 Granger, Gale A., Laguna Beach, CA, United States
 PI US 2001-036458 Al 20011101
 AI US 2001-87583 Al 20010605 (9)
 RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.

DT Journal: Article: (JOURNAL ARTICLE)
 FS MEDL: L; Priority: Journals; Cancer Journals
 LA English
 OS MEDLINE 92097142
 EM 199203
 L2 ANSWER 6 OF 16 USPATFULL
 AN 2001-136177 USPATFULL
 TI Cancer immunotherapy using autologous tumor cells combined with cells
 expressing a membrane cytokine
 IN Graff, Martin R., Richmond, VA, United States
 Granger, Gale A., Laguna Beach, CA, United States
 PA The Regents of the University of California, Oakland, CA, United States
 (U.S. Corporation)
 PI US 6277368 Bl 20010821
 AI US 1997-901225 19970724 (8)
 PRAI US 1996-231088 19960725 (60)
 US 1996-295869 19961029 (60)
 DT Utility
 FS Granted
 LN CNT 2892
 INCL INCLM: 424/093, 210
 INCLS: 424/093, 100; 424/093, 300; 424/093, 700; 424/093, 710; 424/085, 100;
 NCL NCLM: 424/085, 210
 NCLS: 424/085, 100; 424/085, 200; 424/085, 600; 424/277, 100; 435/325, 000
 IC [7] ICM: A61K063-00
 ICS: C12N015-05; A61K035-12; A61K035-19
 EXP 424/193, 21; 424/193, 3; 424/193, 7; 424/193, 71; 424/85, 1; 424/85, 2;
 424/193, 4; 424/277, 1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DT Journal: Article: (JOURNAL ARTICLE)
 FS MEDL: L; Priority: Journals; Cancer Journals
 LA English
 OS MEDLINE 92097142
 EM 199203
 L2 ANSWER 7 OF 16 USPATFULL
 AN 2001-55742 USPATFULL
 TI Adjuvant incorporation into antigen carrying cells: compositions and
 methods
 IN Ravindranath, Mepru H., Los Angeles, CA, United States
 Moron, Donald L., Malibu, CA, United States
 PA John Wayne Cancer Institute, Santa Monica, CA, United States (U.S.
 corporation)
 PI US 6218166 Bl 20010417
 AI US 1995-462106 19950605 (8)
 RLI Continuation-in-part of Ser. No. US 1994-353549, filed on 9 Dec 1994,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 5039
 INCL INCLM: 435/240, 200
 INCLS: 424/240, 100; 424/277, 100; 424/283, 100; 424/184, 100; 424/078, 310;
 NCL NCLM: 435/36, 00
 NCLS: 424/078, 310; 424/150, 100; 424/174, 100; 424/174, 100; 424/184, 100;

424/201.100; 424/240.100; 424/277.100; 424/278.100; 424/283.100;
435/325.000; 435/354.000; 435/372.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2
[7]
ICM: A61K039-000
ICM: A61K039-40; A61K039-395
ICS: A61K035-00; A61K039-40; A61K039-395
EXF 424/240.1; 424/277.1; 424/283.1; 424/278.1;
424/179.1; 424/150.1; 424/201.1; 424/174.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2
[7]
AN 2001-18000 USPATFULL
TI Resenosis/atherosclerosis diagnosis, prophylaxis and therapy
IN Epstein, Stephen E., Rockville, MD, United States
Finke, Toren, Bethesda, MD, United States
Speir, Edith, Amandale, VA, United States
Zhou, Yi Fu, Bethesda, MD, United States
Zhu, Jianhui, Bethesda, MD, United States
Bridle, Lorrie, Loudonville, NY, United States
Pincus, Steven, East Greenbush, NY, United States
Pasteur Merieux Serums et Vaccins, Lyons, France (non-U.S. corporation)
The United States of America as represented by the Department of Health
and Human Services, Washington, DC, United States (U.S. government);
PI US 6183752 B1 20010206 (8)
AI US 1991-796101 DT 19970205 (8)
DT Utility
FS Granted
LN CNT 5757

INCL INCM: 424/199.100

INCLS: 424/199.100; 424/230.100; 424/277.100; 424/093.200; 435/320.100;

NCL NCTM: 514/044.000
NCLS: 424/199.100
IC [7]
ICM: A61K039-245
ICS: A61K039-75; C12N015-38; C12N015-12
EXF 435/173.3; 435/69.3; 435/320.1; 424/199.1; 424/230.1; 424/93.2;
424/277.1; 514/44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2
[7]
AN 1996-13407 USPATFULL
TI Isolated V-beta TCR antibodies
IN Herrend Thierry, Nogent-sur Marne, France
Triebel, Frederic, Seine, France
Roman-Roman, Sergio, Paris, France
Ferradini, Laurent, Paris, France
Rousset Uclaf, France (non-U.S. corporation)

PI US 5830556 19901103 19905059 (8)
AI US 1995-43733 19905059 (8)
RLI Division of Ser. No. US 1995-43383, filed on 14 Apr 1995, now patented,
Pat. No. US 5700907 which is a continuation of Ser. No. US 1992-934530,
filed on 23 Nov 1992, now abandoned
PRAI FR 1991-1613 19910212
FR 1991-4523 19910412
DT Utility
FS Granted
LN CNT 18700

INCL INCM: 435/331.000

INCLS: 530/388.220; 530/387.900; 530/388.750; 435/334.000
NCL NCLM: 435/331.000
NCLS: 435/334.000; 530/387.900; 530/388.220; 530/388.750

IC [6]
ICM: C07K016-08
EXF 530/387.9; 530/388.75; 530/391.3; 530/391.7; 530/388.22; 435/240.27;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2
[7]
AN 97-1120718 USPATFULL
TI Nucleotide sequences coding for variable regions of beta chains of
human T lymphocyte receptors, corresponding peptide segments and the
diagnostic and therapeutic uses
Hercend, Thierry, Nogent-sur Marne, France
Trebel, Frederic, Versailles, France
Roman-Roman, Sergio, Paris, France
Ferradini, Laurent, Paris, France
Roussel Uclaf, France (non-U.S. corporation)
PI US 5700907 1997123
AL US 1995-422383 19950414 (8)
RLI Combination of Ser. No. US 1992-934530, filed on 23 Nov 1992, now
abandoned
FR 1991-4523 19910212
FR 1992-130 19920212
DT Utility
FS Granted
LN CNT 1651
INCL INCM: 530/324.000
INCLS: 536/023.500
NCL NCTM: 530/324.000
NCLS: 536/023.500
IC [6]
ICM: C07K014-125
EXF 435/69.1; 435/240.2; 435/252.3; 435/320.1; 435/225; 530/324; 530/350;
536/23.5; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2
[7]
AN 95-108256 USPATFULL
TI Polypeptide analogs of apolipoprotein E, diagnostic systems and methods
using the analogs
IN Dyer, Cheryl A., Cardiff, CA, United States
Culliss, Linda K., San Diego, CA, United States
Smith, Richard, Del Mar, CA, United States
PA The Scripps Research Institute, La Jolla, CA, United States
(corporation)
PI US 5473039 19951205
AI US 1991-805193 19911209 (7)
RLI Continuation-in-part of Ser. No. US 1991-769629, filed on 30 Sep 1991.
now abandoned which is a continuation-in-part of Ser. No. US
1990-625091, filed on 10 Dec 1990, now abandoned which is a
continuation-in-part of Ser. No. US 1990-40363, filed on 18 Jun 1990,
now patented, Pat. No. US 5168045 which is a continuation-in-part of
Ser. No. US 1990-485158, filed on 26 Feb 1990, now patented, Pat. No. US
5183364 which is a continuation-in-part of Ser. No. US 1989-395732,
filed on 18 Aug 1989, now patented, Pat. No. US 5177189
DT Utility
FS Granted
LN CNT 2890
INCL INCM: 530/324.000
INCLS: 530/326.000; 530/328.000
NCL NCLM: 530/324.000
NCLS: 530/326.000; 530/328.000
IC [6]
ICM: A69K038-00
EXF 530/324; 530/226; 530/321; 514/2; 514/15; 514/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

		FS	Granted
L2	ANSWER 12 OF 16 USPATFULL		
AN	92:61953 USPATFULL	LN.CNT	614
TT	immunostimulating guanine derivatives, compositions and methods	INCL	
IN	Chen, Robert, Belle Mead, NJ, United States	INCUS:	435/007.000;
PA	Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)	INCLS:	435/004.000; 435/029.000; 435/034.000; 435/035.000; 435/519.000;
PI	US 5136030	NCL	436/536.000; 436/542.000; 436/548.000;
AT	1991-691934	IC	[4]
RLI	Division of Ser. No. US 1988-190697, filed on 5 May 1988, now patented.	ICM:	G01N33-53
Pat.	Pat. No. US 5011828 which is a continuation-in-part of Ser. No. US 1985-798629, filed on 15 Nov 1985, now patented, Pat. No. US 4146651	EXF	435/4; 435/7; 435/29; 435/34; 435/35; 436/501; 436/519; 436/536;
	which is a continuation-in-part of Ser. No. US 1983-546679, filed on 1 Nov 1983, now patented, Pat. No. US 4643992	NCLS:	436/542; 436/548
DT	Utility	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	
FS	Granted		
INCL	LN.CNT 2248	LN.CNT	89:23359 USPATFULL
INCLM:	536/024.000	TI	late differentiation antigens associated with helper T lymphocyte
NCLM:	536/027.110	IN	function
NCLS:	536/027.810	Suci-Foca, Nicole, Cliffside Park, NJ, United States	
IC	[5]	PA	King, Donald W., Chicago, IL, United States
	ICM: C07H021-00	The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)	
EXF	536/26; 536/24	PI	US 4816104
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	AI	US 1986-830697
L2	ANSWER 13 OF 16 USPATFULL	DT	Continuation-in-part of Ser. No. US 1985-752397, filed on 5 Jul 1985
AN	91:33348 USPATFULL	FS	Utility
TI	immunoactivating guanine derivatives, compositions and methods	LN.CNT	Granted
IN	Goodman, Michael, 6455 Calle de Lagrima, Rancho Santa Fe, CA, United States 92067	INCL	1066
Weigle, William, 13750 Rueette Le Parc, Apt. C, Del Mar, CA, United States 92014	INCUS:	435/240.270	
Bell, Stanley, 732 Braeburn Ln., Narberth, PA, United States 19072	NCLM:	530/387.000; 424/085.800; 435/068.000; 435/172.200; 935/104.000;	
Chen, Robert, 39 Beverly Dr., Belle Mead, NJ, United States 08502	NCLS:	935/110.000	
Robins, Roland K., 3 Titan, Irvine, CA, United States 92715	IC	[4]	
Hennen, William J., 2306 Long Dr., Bryan, TX, United States 77802	ICM:	C12N005-00	
US 1988-190597	EXF	435/240; 435/241; 435/68; 435/70; 435/172.2; 435/240.27; 935/104;	
PI	US 1988-190597	935/110; 530/387; 424/85	CAS INDEXING IS AVAILABLE FOR THIS PATENT.
RLI	Continuation-in-part of Ser. No. US 1985-798629, filed on 15 Nov 1985, now patented, Pat. No. US 4746651 which is a continuation-in-part of Ser. No. US 1983-546679, filed on 1 Nov 1983, now patented, Pat. No. US 4643992	LN.CNT	
DR	Utility	LN.CNT	
FS	Granted	LN.CNT	
INCL	LN.CNT 2339	LN.CNT	
INCLM:	514/045.000	LN.CNT	
NCLM:	514/045.000	LN.CNT	
IC	[5]	LN.CNT	
ICM: A61K031-70	LN.CNT	86:47998 USPATFULL	
ICOS: C08B031-00	TI	biocompatible method for in situ production of functional platelets and	
514/15; 536/24	IN	product produced thereby lacking immunogenicity	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	Rodey, Glenn E., Chesterfield, MO, United States		
L2	ANSWER 14 OF 16 USPATFULL	PA	American National Red Cross, Washington, DC, United States (U.S. corporation)
AN	89:25778 USPATFULL	PI	US 4608255
TT	late differentiation antigen associated with helper T lymphocyte function	AI	US 1985-696657
IN	Suci-Foca, Nicole, Cliffside Park, NJ, United States	DT	Utility
	King, Donald W., Chicago, IL, United States	FS	Granted
PA	The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)	LN.CNT	385
PI	US 4818669	INCUS:	424/101.000
AI	19890404	NCLM:	422/024.000; 435/002.000
DT	US 1985-752397	IC	[4]
Utility	19850705 (6)	ICM: A61K035-14	
		EXF	424/101; 435/2; 422/24; 426/748
		CAS INDEXING IS AVAILABLE FOR THIS PATENT.	

=> s cognate and proto oncogene

L3 803 COGNATE AND PROTO ONCOGENE

=> d his

(FILE 'HOME' ENTERED AT 09:44:15 ON 02 JUL 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 09:44:39 ON 02 JUL 2002

L1 0 S ALLOGENIC DONOR CELL? AND TRANSGENE?

L2 16 S IMMUNOGEN AND ALLOGENIC CELL?

L3 803 S COGNATE AND PROTO ONCOGENE

=> s l2 and l3

L4 1 L2 AND L3

=> d 14

L4 ANSWER 1 OF 1 USPATFULL

AN 2002:133468 USPATFULL

TI 32 human secreted proteins

IN Ni, Jian, Germantown, MD, UNITED STATES

Baker, Kevin P., Darneetown, MD, UNITED STATES

Birrell, Charles E., North Potomac, MD, UNITED STATES

Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Fischella Michele, Bethesda, MD, UNITED STATES

Komatsoulis, George A., Silver Spring, MD, UNITED STATES

LaFleur, David W., Washington, DC, UNITED STATES

Moore, Paul A., Germantown, MD, UNITED STATES

Olsen, Henrik S., Gaithersburg, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Rubin, Steven M., Olney, MD, UNITED STATES

Soppet, Daniel R., Centreville, VA, UNITED STATES

Young, Paul E., Gaithersburg, MD, UNITED STATES

Wei, Ping, Brookville, MD, UNITED STATES

Pi Florence, Kimberly A., Rockville, MD, UNITED STATES

PI US 2002068119 AI 20020606

AI US 2001-800729 AI 20010308 (9)

RLI Continuation-In-part of Ser. No. WO 2000-US26013, filed on 22 Sep 2000, UNKNOWN

PRAI US 1999-155709P FS 19990924 (60)

DT UTILITY

FS APPLICATION

LN..CNT 36936

INCL INCHM: 435/069-100

NCL INCIS: 435/007-100; 435/325-000; 435/183-000; 536/023-500; 530/388-100

NCI NCLM: 435/069-100

IC [7] ICM: C12R021-02

ICS: C12N005-06; G01N033-53; C07H021-04; C12N009-00

=> d his

(FILE 'HOME' ENTERED AT 09:44:15 ON 02 JUL 2002)

FILE 'MEDLINE, CANCERLIT, EMBASE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 09:44:39 ON 02 JUL 2002

L1 0 S ALLOGENIC DONOR CELL? AND TRANSGENE?

L2 16 S IMMUNOGEN AND ALLOGENIC CELL?

L3 803 S COGNATE AND PROTO ONCOGENE

L4 1 S L2 AND L3

=> s transgene and cognate and proto oncogene

L5 130 TRANSGENE AND COGNATE AND PROTO ONCOGENE

=> s 15 not PY=>1998

5 FILES SEARCHED..

L6 10 L5 NOT PY=>1998

=> d 16 1-10

L6 ANSWER 1 OF 10 MEDLINE

AN 96402025 PubMed ID: 8924763

DN 96402025 Published ID: 8924763

TI The programmed cell death of an immature thymocyte cell line transgenic for an alpha beta TCR and the c-myc proto-oncogene.

AU Murdjeva M; Tanaka Y; Norton T; Kiousis D

CS Laboratory of Molecular Immunology, National Institute for Medical Research, London, UK.

SO DEVELOPMENTAL IMMUNOLOGY, (1996) 4 (4) 279-88.

CY Journal code: 9200624. ISSN: 1044-6672.

ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199610

ED Entered STN: 19961219

ED Last Updated on STN: 19961219

Entered Medline: 19961025

L6 ANSWER 2 OF 10 MEDLINE

AN 96305183 PubMed ID: 8691153

DN 96305183 Positive and negative selection invoke distinct signaling pathways.

TI Alberola Ila J; Hogquist K A; Swan K A; Bevan M J J; Perlmutter R M

AU Howard Hughes Medical Institute, Seattle, Washington, USA.

CS NC DOI-09537 (NCTI)

SO JOURNAL OF EXPERIMENTAL MEDICINE, (1996 Jul 1) 184 (1) 9-18.

CY Journal code: 2885109R. ISSN: 0022-1007.

United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199608

ED Entered STN: 19960911

ED Last Updated on STN: 20000303

Entered Medline: 19960829

L6 ANSWER 3 OF 10 CANCERLIT

AN 96402025 CANCERLIT

DN 96402025

TI The programmed cell death of an immature thymocyte cell line transgenic for an alpha beta TCR and the c-myc proto-oncogene.

AU Murdjeva M; Tanaka Y; Norton T; Kiousis D

CS Laboratory of Molecular Immunology, National Institute for Medical Research, London, UK.

SO DEVELOPMENTAL IMMUNOLOGY, (1996) Vol. 4, No. 4, pp. 279-88.

Journal code: BJR. ISSN: 1044-6672.

DT Journal; Article; (JOURNAL ARTICLE)

FS Priority Journals

LA English

OS MEDLINE 96402025

EM 199612

L6 ANSWER 4 OF 10 CANCERLIT

AN 96305183 CANCERLIT

DN 96305183

TI Positive and negative selection invoke distinct signaling pathways.
AU Alberto Ila J.; Hogquist K.A.; Swan K.A.; Bevan M.J.; Perlmutter R.M.
CS Howard Hughes Medical Institute, Seattle, Washington, USA.
NC CA-09337 (NCL)
SO JOURNAL OF EXPERIMENTAL MEDICINE. (1996). Vol. 184, No. 1, pp. 9-18.
Journal code: JVW. ISSN: 0022-1107.
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDL; L; Priority; Journals: Cancer Journals
LA English
OS - MEDLINE 96305183
EM 199609

L6 ANSWER 5 OF 10 USPATFULL
AN 97:12:056 USPATFULL
TI Cell death regulator
IN Kormeyer, Stanley J., Clayton, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PT US 5706538
AI US 1994-2481819 19940525 (8)
RLI Continuation-in-part of Ser. No. US 1993-112208, filed on 26 Aug 1993, now abandoned

DT Utility
FS Granted
LN.CNT 403A
INCL INC1M: 435/006.000
INCL INC1S: 435/007.100; 435/007.200; 435/007.210; 435/007.310; 435/007.800;
INCL INC2M: 435/240.100; 435/240.200; 435/069.100; 435/172.300; 530/350.000;
INCL INC2S: 436/501.000
NCL NCLM: 435/006.000
NCL NCLS: 435/069.100; 435/069.1; 435/172.3; 530/350.000; 435/477.000; 436/501.000; 530/350.000

IC [6] ICS: C12Q001-68
ICM: GO1N03-38; GO1N03-53; C12P021-02; C12N005-02; C12N005-12;
EXF C07K014-475
EXF 435/16; 435/7.1; 435/7.2; 435/7.21; 435/7.31; 435/7.8; 435/240.1;
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 10 USPATFULL
AN 97:10943 USPATFULL
TI Cell death regulators
IN Kormeyer, Stanley J., St. Louis, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PT US 5691179
AI US 1993-112208
DT Utility
FS Granted
LN.CNT 323B
INCL INC1M: 435/240.100
INCL INC1S: 435/240.200; 435/252.300; 435/254.110; 435/320.100; 435/172.300;
NCL NCLM: 435/325.000
NCL NCLS: 536/023.500; 536/024.310; 536/024.330

IC [6] ICM: C12N001-15
ICM: C12N001-21; C12N005-10; C07H021-00
EXF 536/23.4; 536/23.5; 536/24.31; 536/24.33; 435/252.3; 435/252.33;
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 10 USPATFULL
AN 97:42763 USPATFULL
TI Transition in transcriptional activation by intracellular hormone receptors at the tumor stage of dermal fibrosarcoma development
IN Hashman, Douglas, San Francisco, CA, United States
PA Yamamoto, Keith R., San Francisco, CA, United States
PA Vilavaco, Maria d. M., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5631133
AI US 1995-439813
DT Utility
FS Granted
LN.CNT 2011
INCL INC1M: 435/006.000
INCL INC1S: 435/069.400; 435/172.100
NCL NCLM: 435/006.000
IC [6] ICM: C12Q001-68
ICM: C12P021-00; C12N015-65; C12N005-10
EXF 435/69.1; 435/252.3; 436/64; 536/51
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 10 USPATFULL
AN 97:33647 USPATFULL
TI Bcl-1/x/Bcl-2 associated cell death regulator
IN Kormeyer, Stanley J., Clayton, MO, United States
PA Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 5622852
AI US 1994-333565
DT Utility
FS Granted
LN.CNT 3763
INCL INC1M: 435/325.000
INCL INC1S: 435/252.300; 435/252.330; 435/254.110; 435/348.000; 535/023.400;
NCL NCLM: 435/325.000
NCL NCLS: 536/023.500; 536/024.310; 536/024.330

IC [6] ICM: C12N001-15
ICM: C12N001-21; C12N005-10; C07H021-00
EXF 536/23.4; 536/23.5; 536/24.31; 536/24.33; 435/240.1; 435/254.11; 935/66; 935/88; 935/11/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 10 USPATFULL
AN 97:7825 USPATFULL
TI Interaction of RAF-1 and 14-3-3 proteins
IN Freed, Ellen, Oakland, CA, United States
PA Ruggieri, Rosamaria, San Francisco, CA, United States (U.S. corporation)
PI US 5597719
AI US 1994-276151
DT Utility
FS Granted
LN.CNT 2208
INCL INC1M: 435/194.000
NCL NCLM: 435/194.000
IC [6]
EXF 435/194
ICM: C12N009-12
EXF 435/194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 10 USPATFULL
AN 97:42763 USPATFULL
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS
AN 1997:555092 CAPLUS
DN 127:239522
TI The programmed cell death of an immature thymocyte cell line transgenic
for an alpha/beta TCR and the c-myc proto-oncogene
AU Murdjeva, Marianna; Tanaka, Yujiro; Norton, Trisha; Klioussis, Dimitris
CS Laboratory of Molecular Immunology, National Institute for Medical
Research, London, NW7 1AA, UK
SO Developmental Immunology (1995), 4 (4), 279-288
CODEN: DEIMET; ISSN: 1044-6672
PB Harwood.
DT Journal
LA English